OOIR: Observatory of International Research

Papers

(The median citation count of ESMO Open is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Table of Contents	244
Table of Contents	148
Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis	147
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study	137
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort	103
Longer survival with precision medicine in late-stage cancer patients	100
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes	99
Globalization of clinical trials in oncology: a worldwide quantitative analysis	98
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations	97
Table of Contents	97
164P Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors	93
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	90
61P Pazopanib in the real-world setting: Data from the Italian national registry	82
22P Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma	82
60P The diagnostic pathway of sarcoma patients: Results from the QUEST study in the Netherlands and the United Kingdom: A cohort study	82
169P A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on mole	73
70P Total neoadjuvant vs standard perioperative cisplatin/doxorubicin chemotherapy in patients with extremities osteosarcoma: A single-center cohort study	73
104P Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma	72
73P Proton radiotherapy in treatment of desmoid tumors	72
OP01-3 A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)	71
5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations	70
32P Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients	69
OP02-1 Safety and efficacy of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracycline and taxane in real-world clinical practice: Data from post-marketing	68
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	67
104P Multi-omic profiling and real-time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation	62

100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	60
91P Management challenges of extremity sarcomas in under-resourced settings: The first survey-based study in Morocco	57
30P Deep learning approach for discovering new predictive histological features of immunotherapy response	56
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	55
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	54
111P A novel immune cell signature for predicting pleomorphic sarcoma prognosis	53
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	52
European Society for Medical Oncology (ESMO)	51
PP106 Identifying apoptosis-inducing genes in human osteosarcoma cell lines and their potential use in immunotherapy	49
107P Inhibition of hydrogen sulfide biosynthesis influences mitochondrial biogenesis in breast cancer	48
PP157 Metformin prevents tumor cell growth and invasion of human hormonal breast cancer cells via the diabetes-related gene inhibition	48
PP171 Therapeutic influence of simvastatin on MCF-7 and MDA-MB-231 breast cancer cells via mitochondrial depletion and improvement in chemosensitivity of cytotoxic drugs	48
100P Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma	47
116P Targeting mitochondrial biogenesis in the ‘CYBRID’ model of chronic lymphocytic leukemia for improving cancer related fatigue after chemotherapy	46
17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients	45
25O Phase I tolerability, persistence and pharmacodynamic (PD) profile of IV-administered next-generation adenoviral vectors supports clinical expansion in solid cancers	44
34P Cocktail peptide vaccines targeting cancer stem cells for enhanced therapeutic efficacy in oral cancers	43
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	43
104P A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung	43
35P Beyond microsatellite testing: Tumor mutational burden, should it be routine in patients with GI cancers?	42
Acknowledgements	40
Title Page	40
24P New hybrid camptothecin-based molecules: Promising antitumor agents for the treatment of hematological malignancies	40
18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated	40
24P Sinonasal neuroendocrine tumors: Analysis of therapeutic strategies in an ultra-rare tumor	40
29P Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)	40
36P Development of patient-derived explant model as a robust preclinical tool to predict the efficacy of ICB-based immunotherapy in colorectal cancer patients	40
23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC)	39
42P Conflicting results of BCL2 based on HER2 status in patients with breast cancer	39
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	39
45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors	37
59P Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma	37
8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study	37
51P Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast	37
9P The efficacy of HIF-1 alpha expression in the response to first-line standard chemotherapy and bevacizumab treatment in patients diagnosed with metastatic cervical cancer	37
55P High snail expression and activation of mTOR promote liver recurrence after hepatic metastasectomy for colorectal cancer	36
67P Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma	36
46P Dynamics of ROS1 kinase binding: Insights into DFG-out tyrosine kinase inhibitors and effects of allosteric-pocket mutations	36
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	36
43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors	36
40O Diagnostic trajectories of rare cancer patients in the Netherlands: Results from a nationwide cross-sectional survey	35
46P The pre-diagnostic general practitioner care of sarcoma patients: A real-world data study	35
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	35
90P RAS mutant colorectal cancer in Portuguese tertiary care: Molecular landscape and patterns of metastatic spread	35
55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse	35
70P Combination of EGFR-TKI and chemotherapy versus EGFR-TKI monotherapy as neoadjuvant treatment of stage III-N2 EGFR-mutant non-small cell lung cancer	35
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	35
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	34
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment	34
Editorial Board	33

63P Systemic therapy for KIT/PDGFRA wild-type GIST	33
85P Long-term experience in the management of solitary fibrous tumors in a sarcoma reference centre	33
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	33
70P Prognosis and reasons for non-surgical treatment in >70 years old patients with soft-tissue sarcoma treated without surgery	33
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	32
9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)	32
15P Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study	31
11P Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01	30
22P Evaluation of co-mutation in EGFR-mutant non-small cell lung cancer by next generation sequencing (NGS): Retrospective cohort study in South Korea	30
74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study	30
124P Automated measurement of coronary artery calcifications predicts survival in resected stage I lung cancer	29
98TiP Safety and efficacy of aumolertinib combined with anlotinib as 1st-line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation	29
76P Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells	29
105TiP Adebrelimab combined with famitinib in the treatment of PD-L1≥50% advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01)	29
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	29
103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 2	29
80P LILRB2+ defines a monocyte subset which identifies responders of PD-1/PD-L1 immunotherapy with or without chemotherapy in NSCLC	29
126P Adjuvant aumolertinib for resected EGFR-mutated stage IA2-IIIA non-small cell lung cancer: Updated results from a multiple-center real-world experience	28
43P Updated efficacy and circulating tumour (ct)DNA analysis in patients (pts) with TRK fusion lung cancer treated with larotrectinib (laro)	28
246P Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis	28
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	28
116P Role of extracorporeal irradiation in primary malignant bone tumors	27
101P Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center	27
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	27
108P Safety and efficacy of fruquintinib (FRU)-based therapy in patients (Pts) with advanced or metastatic osteosarcoma: A real-world study	27
62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial	27
121P Radiological staging with FDG-PET vs WB-MRI in Ewing sarcoma in the era of precision treatment	27
102P Redefining radiological response assessment in soft tissue sarcoma	27
49P Perioperative circulating tumor DNA redefines induced oligometastatic non-small cell lung cancer at the molecular level	27
133P Molecular profile and actionability of sarcomas with next-generation sequencing: Insights from a single institution in Brazil	26
18P Decoding the interplay of deubiquitinating enzymes (DUBs) in metastasis and chemoresistance of gynaecological cancers	26
144P Influence of tumor-infiltrating T-cells' characteristics on the survival of patients with primary choroid melanoma	26
149P Treatment landscape for desmoid tumors: Desmoid Tumor Research Foundation Natural History Study	26
124P Ewing's sarcoma in adolescents and adults: 12-year experience from a reference center in Peru	26
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	26
142P AI-based approaches to predict early response in unresectable LA-NSCLC patients undergoing chemoradiation	25
66P Digital profiling of immune biomarkers: Relation to anthracycline benefit	25
130P Whole-body PET imaging to study bone metabolism in pre- and post-treatment lung cancer patients	25
145P I-SAbR in unresectable LA-NSCLC patients receiving durvalumab in START-NEW-ERA non-randomised phase II trial	25
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	24
81P Genetic association of ABCG2 polymorphisms on triple-negative breast cancer susceptibility and prognosis	23
OD1-4 Pilot study examining the feasibility and safety of exercise intervention during palliative chemotherapy in patients with advanced gastrointestinal cancer	23
85P Microbiome analysis in patients with breast cancer via an oral prebiotics therapy	23
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	23
101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analy	23
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	23
KSMO Officers and Information	22
272P Competitive cause of death in elderly breast cancer survivors	22
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	22
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	22
OP06 TCTP is a target for cancer immunotherapy-modulating myeloid-derived suppressor cells	22
203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial	22
OP02 Clinical characteristics and germline mutation spectrum of RB1 in Vietnamese patients with retinoblastoma	22
PP015 Vitis vinifera seed extract prevents tumorigenesis through interleukin-1 alpha in triple-negative breast cancer models	22
270P Real-world data of cardiac disorders screening in breast cancer survivors	22
Title Page	21
PP040 Overcoming trastuzumab resistance by exploiting the synthetic lethal interaction of DNA damage response pathway in HER2-positive cancers	21
Editorial Board	21
13P Cervical cancer screening in a basic health unit in South of Brazil: Impact of the COVID-19 pandemic	21
PP096 A prospective study to evaluate the role of cell free DNA and DNA integrity index in assessing the response to neoadjuvant chemotherapy in patients with breast carcinoma	21
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	21
12P Tisotumab vedotin in recurrent or metastatic cervical cancer	21
PP202 Stem cell-like subtype from developmental hierarchies of fetal liver shows clinical relevance with prognostic significance in hepatocellular carcinoma	21
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	21
OP07 Differential RNA expressions of specific immune-related genes and proximity of tumor cells from intratumoral M1 macrophages are closely linked to therapeutic outcomes of immune checkpoint inhibit	21
7P Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC): A single-centre prospective experience	21
54P Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC	20
72P MDM alterations in patients with advanced or metastatic cancers	20
4P Evaluation of antitumor activity and immunogenic cell death (ICD) induction by MORAb-202 (farletuzumab ecteribulin) in human ovarian cancer (OV) models	20
8O Clinical implications of clonal hematopoiesis in the tumor microenvironment of non-small cell lung cancer	20
1O SPICE: Probabilistic reconstruction of copy-number evolution in metastatic cancers	20
157P Comparison of survival outcomes in young patients with breast cancer receiving contralateral prophylactic mastectomy versus unilateral mastectomy	20
3O Are targeted therapies effective in the relapsed or metastatic cancer setting? A Cochrane meta-analysis	20
169P Hypofractionated radiotherapy versus conventional radiotherapy in postmastectomy breast cancer patients: A single institution non-randomized study, prospective study	20
90P Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials	20
9O Pancreatic cancer risk in individuals with newly diagnosed diabetes: Insights from the AMORIS cohort in Sweden	20
Acknowledgements	19
20P Effects of Apis dorsata honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cell	19
244P Eribulin in Chinese advanced breast cancer patients intolerant to first-/second-line taxane-based therapy: The patient-reported outcomes	19
167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort	19

55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	19
22MO Homologous recombination gene mutations in uterine serous cancer: A phenotype of the hereditary breast and ovarian cancer syndrome?	19
175P Breast cancer in neurofibromatosis type 1: A retrospective review in the Portuguese population	19
64P Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions	19
170P Comparison of the outcome between photo-medicine based dual method vs RI method in axillary sentinel lymph node operation for breast cancer patients after neoadjuvant chemotherapy	19
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial	19
31P Uterine cancer metastasis patterns and racial disparities: A SEER database population study 2010-2019	19
163P Long-term assessment of secondary malignancies (2ndM) in women with breast cancer (BC) and germline TP53 mutations (gTP53m) treated with radiation therapy (RT)	19
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	18
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	18
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	18
52P Real-world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group	18
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	18
54P Fallopian tube cancer and ovarian cancer: A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape	18
57P International ovarian tumor analysis (IOTA) simple ultrasound rules and risk of malignancy index in differentiating benign from malignant ovarian masses	18
143P A single institution’s real-world experience with the neoadjuvant Keynote-522 treatment regimen	18
41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer	17
51P Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations	17
231P Trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK: Real-world data	17
78P Electronic tool for high grade adverse event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM)	17
176P Awareness & knowledge pertaining to genetic breast cancer in developing countries: A questionnaire based prospective study of 300 patients	17
254P The invasive lobular cancer of the breast (ILC): A collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC)	17
219P Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE registry	17
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	17
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	17
47P Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy (former platinum-resistant)	17
228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial	17
241P APOBEC3-induced PIK3CA mutations predict better clinical outcomes with PI3K inhibitors in patients with PIK3CA-mutated advanced breast cancer	17
13O Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients: A TMRG and GINECO group study	16
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	16
55P Evolution of genetic testing after ovarian cancer (OC) diagnosis	16
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	16
129P Repurposing existing therapies for adrenal cancer: Unlocking new possibilities	16
134P Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance	16
114P Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer	16
78P Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response	16
129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort	16
94P Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC	16
132TiP Double-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors (DT): The RINGSIDE phase III study design	16
125P Sirolimus experience in adult patients with vascular anomalies	16
139P Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection	16
80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)	16
133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)	16
66P PD-L1 expression following neoadjuvant chemotherapy is upregulated and serves as a prognostic factor in patients with advanced high-grade serous ovarian carcinoma	16
41P Addressing the unmet need for salivary gland cancers in the UK and beyond	16
127P Outcomes of advanced chordoma from dedicated sarcoma medical oncology clinic from a tertiary care center in North India	16
136P Molecular correlates of drug response to guide therapy in TNBC	16
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	15
143P Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma	15
89P Inclusion of racial and ethnic minorities in European breast cancer clinical trials	15
79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer:	15
66P Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma	15
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	15
141P Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC	15
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	15
32P Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma	15
62P Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia	15
5P Long term outcome of surgical management for vertebral hemangioma presenting with myelopathy	15
58P Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype	15
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	15
52P Clinical characterization of HER2 low in patients with lobular breast cancer (ILC)	15
CRUK	15
60P Spindle cell sarcomas with tyrosine kinase rearrangement	15
Immune checkpoint inhibitors alone or in combination for endometrial mismatch repair-deficient/MSI-high population	14
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?	14
Editorial Board	14
COVID-related disruption in mammographic screening: a year later	14
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)	14
Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma	14
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030	14
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	14
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival	14
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	14
Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores	14
Editorial Board	14
First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience	14
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group	13
Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases	13
Perspectives of oncology residents on Master's Degree in Science (MSc) programs: a national descriptive study by the French Association of Residents in Oncology (AERIO)	13
Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible	13
Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices	13
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma	13
Dignity of Science and the use of ChatGPT as a co-author	13
Editorial Board	13
Editorial Board	13
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial	13
Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?	13
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis	13
Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.	13
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	13
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	13
Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies	13
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	13
216TiP A phase II study of consolidation serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer (ASTRUM-LC01)	12
221P Single-cell transcriptomics reveals CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small cell lung cancer	12